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Summary.-In confirmation ofother studies it has been shown that antibody directed
againstthetumour specifictransplantation-type antigens (TSTAs) cannot be detected
in rats with a tumour growing intramuscularly but appears within a few days after
excision of the tumour. Circulating antibody is found in the serum of rats with
lymph node metastasis following excision of the primary. Absorption by the intra-
muscular tumour ofcirculating antibody does not account for the absence ofantibody
since the antibody levels in thoracic duct lymph in rats with tumours in the leg are
also very low and rise rapidly after tumour excision. Antibody is released by the
draining nodes directly into the lymph and must pass through the thoracic duct
before entering the blood. Under these conditions low levels of antibody activity
in lymph cannot be ascribed to absorption by the tumour.
It is postulated that TSTA is released from the tumour into the lymph. Follow-
ing injection oftumour cells into immunized rats the level of antibody falls and this is
attributed to release of TSTA from the injected cells. The possible role of antigen
release from tumours in determining the host reaction to the tumour is discussed.
ANTIBODIES to tumour-specific trans-70we decided to test whether absorption of
plantation antigens (TSTA) of chemically- antibodies by the tumour occurred by
induced sarcomata in rodents are present determining the antibody levels in the
in serum after excision of the tumour but thoracic duct lymph of rats with tumours
cannot be detected while growing tumour in the leg.
is present (Pilch and Riggins, 1966; The nodes draining such tumours are
Harder and McKhann, 1968; Thomson, highly stimulated (Alexander et al., 1969)
Steele and Alexander, 1973; Baldwin, and contain many plasma cells. Their
Embleton and Robins, 1973). The expla- efferent lymph, which would be expected
nation has been advanced that this to contain antibodies, is discharged
phenomenon-is due to absorption of the directly into the thoracic duct before
circulating antibody by the tumour reaching the tumour. Therefore, should
(Harder and McKhann, 1968; Ran and the absence of antibodies in the blood of
Witz, 1970; Buchsbaum, 1972). If tumour-bearing animals be due to absorp-
absorption were, in fact, the principal tion by the tumour, then antibodies
mechanism, one would expect the tumour should be detected in moderate to high
cells to be covered with antibodies. Our concentration in the thoracic duct lymph
experiments failed to show antibodies of such animals. However, in the study
bound to the cell surface of tumours to be reported here measurable antibody
growing in vivo. However, such a nega- levels in the lymph are very low while the
tive finding is not conclusive. Therefore tumour is in situ and rise when the
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tumour is excised. Consequently, mech-
anisms other than absorption by the
tumour must be responsible for the
absence of measurable amounts of anti-
body in the blood in tumour-bearing
animals.
The recent finding (Thomson et al.,
1973) that complexes ofTSTA and specific
antibody with soluble antigen in excess
can be found in the serum of rats with
sarcoma suggests that one factor respon-
sible for the failure to detect serum anti-
body in the tumour-bearing animals is the
release by the tumour of soluble antigen
into the circulation. The experiments
to be described suggest that soluble TSTA
escapes not only into the circulation but
also into the afferent lymph, where it
combines immediately with antigen-bind-
ing cells and specific antibody formed by
the plasma cells present in the draining
nodes. The release and combination of
soluble antigen with antibody diminish
the quantity of free antibodies discharged
from these nodes into the efferent lymph.
In order to carry out these investiga-
tions it was necessary to collect specimens
of thoracic duct lymph over a period of
several days. Consequently, a method
was devised of inserting a T-piece into
the thoracic duct which allows daily
sampling of lymph without causing a
significant imbalance in the body fluids.
Antibodies directed to antigens on the
surface of the tumour cell were measured
principally by mixed haemadsorption with
a 51Cr-labelled indicator cell.
MATERIALS AND METHODS
Inbred male hooded rats were used
throughout at 12-18 weeks of age and their
genetic identity was established periodically
by skin grafting. A methylcholanthrene-
induced fibrosarcoma (MC-I) was selected for
study because of its marked antigenicity and
non-crossreactivity, as judged by standard
transplantation tests (Thomson et al., 1973).
The tumours were usually passaged by
trocar implant. However, in some experi-
ments where exact cell numbers were
required, single cell suspensions prepared by
0-05% trypsin, 0.05% collagenese and DNase
were used. The tumour was grown intra-
muscularly in a hind limb and excised
surgically when 2-4 cm in diameter, 14-28
days after initial transplantation. Early
generations of MC-I sarcoma were stored at
liquid nitrogen temperature and withdrawn
at intervals for passage in syngeneic hooded
rats. Tests were carried out on tumours
from generation 4-8. Other chemically-
induced tumours were used for comparison.
Samplingofperipheralblood. The animals
were bled from a tail vein at various times
before and after tumour excision and the
sera were frozen until tested. Each experi-
mental group consisted of 25-40 rats and
anti-TSTA antibody activity in the serum
was determined on 3 different samples. The
results from all animals were pooled and
plotted as a single result for each day since
the variation between animals was less than
10%.
Preparation of immune serum specific to
the MC-I sarcoma was raised by growing
viableMC-I cellsintramuscularly and excising
the resulting tumour surgically. Subse-
quently, the syngeneic rats were given
repeatedinjectionsofan(15,000rad)irradiated
brei of MC-I sarcoma over 12 weeks and the
rats were bled one week after the last injec-
tion.
Sampling of thoracic duct lymph.-A
modification of the thoracic duct cannulation
method described by Delorme et al. (1969)
was designed by one of us (S.A.E.) to allow
the daily sampling of lymph from rats
without the undue depletion of circulating
lymph occasioned by continual drainage. This
new technique is simpler than the only
alternative method of a thoracic duct shunt
(Girardet, 1970) and allows continuous or
intermittent access to a stable thoracic duct
lymphatic circulation over a prolonged
period.
The surgical procedures used to expose
the duct were as previously described
(Delorme et al., 1969). The cannula em-
ployed was in the form of a " T " tube made
by glueing a length of nylon flexible tubing
(size 1, Portex) over a nick cut in the side ofa
short length of the same tubing. The ends
of the short arm were bevelled with a scalpel
at 2 mm and 5 mm from the junction. A
single opening was made in the thoracic duct
with scissors, and through this the 5 mm end
of the T tube was introduced and pushed
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cephalad. The 2 mm end was then slipped
under the raised flap of the same opening
and pushed caudad. In this position the T
tube was held in place by the natural elasti-
city of the duct and was further secured by
silk sutures around each arm of the T. Five
to 10 ml of lymph were collected from eachi
animal per day in iced siliconized tubes
containing 0 5 ml of heparinized buffered
saline, spun at 800 g for 5 minutes and the
supernatant removed. The low density f,-
lipids were removed by the addition of 0-02
ml of 10% dextran sulphate and 01 ml of
1 mol/l calcium chloride per ml of sample.
After 1 hour at 4°C the sample was centri-
fuged at 1000 g for 15 minutes, the precipitate
was discarded and the protein concentration
was determined by spectrophotometric absor-
bence at A280 nm (albumin standard).
After the supernatant was dialysed over-
night against 3 changes ofphosphate buffered
saline (PBS) pH 7-3 at 4°C it was frozen until
used for assay. All samples were tested for
anti-TSTA antibody at approximately the
same protein concentration. In the experi-
ments in which the kinetics of the anti-TSTA
antibody response were followed daily,
samples were drawneachdayfrom aminimum
of 3 animals. The cannulated animals were
rotated so that no animal was drained longer
than 5 days and one sample was always
obtained from an animal that had been
cannulated in the previous 24 hours. All
samples were tested individually for anti-
TSTA antibody but the results did not vary
by more than 10%/ on samples drawin on the
same day; therefore they are plotted as a
single point.
Measurement of antibody activity by the
haemadsorption test.-The technique used was
a modification of the method of Tachibana,
Worst and Klein (1970). The extenlt of
linking of sheep erythrocytes (srbc) coated
with anti-srbc serum and anti-globulin serum
to tumour cells treated with serum or lymph
was assayed by labelling the srbc with 50Cr
and counting the radioactivity adherent to
the cultured sarcoma cells.
The rat anti-srbc serum and the rabbit
anti-rat y-globulins were prepared and the
srbc were sensitized with the antisera and
labelled with 5'Cr as previously described
(Thomson et al., 1973). The srbc were
sensitized with a concentration of antisera
(rat anti-srbc 1: 200) (rabbit anti-rat y-
globulin 1: 30) which gave the highest mixed
haemadsorption index (MHI) when the MC-I
sarcoma cells were exposed to either MC-I
immune or post-excision sera.
The sera and lymph were tested on MC-I
sarcoma growing in culture (3 cm Falcon
dishes) as previously described (Thomson et
al., 1973). Control sera and lymph were
obtained from normal animals in addition
to animals bearing unrelated tumours or after
these were excised. Sera and lymph were
also obtained from animals immunized with
complete Freund's adjuvant or BCG. The
quantity of antibody bound by the tumour
cells was expressed as the mixed haemadsorp-
tion index (MHI)-
counts/min from 5'Cr in cultures
MHI treated with test serum or lymph counts/min from 51Cr in cultures
treated with control serum or lymph
A value of the MHI of 1-3 or greater was
considered significant since comparable con-
trols of different types never gave a value
greater than 1-2. All tests were carried out
in triplicate and lymph and serum were
routinely tested at 1: 3-5-4 dilution.
Membraneimmunofluorescence assay-The
indirect membrane immunofluorescence test
was performed on viable single cell tumour
suspensions obtained from finely minced
solid tumours with 0-04% trypsip and
0-04% collagenase in the presence of a small
amount of DNase (Thomson et al., 1973). In
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FIG. 1.-Specific antibody to MC-1 sarcoma at
various dilutions as determined by the 5'Cr-
labelled-mixed haemadsorption test. In hyper-
immune serum (0 0 ), in serum 14 days after
MC-I excision (0 O) and serum from
MC-I tumour-bearer ( O- - 0).
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the present study, this test wsras used for
lymph at dilut,ions of 1: 2 since in the
nixed haemadsorption test (at this dilution)
the cells became detached from the plates.
Controls similar to those already described
were used and fluorescent index (FT) -was
calculated similar to MHI. Control lymph
samples diluted 1: 2, i-epeatedly gave an Fl
of less than 2-2.
Single cell suspensions of MC-I sarcoma
were prepared mechanically from solid
tumours gro-wing intramuscularly. This wAas
performed by finely mincing the tumour with
scissors and stirring for 30-45 minutes in
medium 199 at R.T. The cells -were then
examined for cell bound imnmunoglobulins
by incubating the cells with fluorescein
conjugated rabbit, anti-rat y-globulin.
RESULTS
1. Comparison of antibody levels to surface
components in the serum of animals with a
growing tumour and following surgical
excision of the tunour
Fig. 1 gives the mixed haemadsorp-
tion in(lex (MHI) as a function of serum
concentration. Experiments with con-
trol sera indicate that values of a MHI
greater than 1l2 are evidence for the
presence ofspecific antibody oIn the surface
of the tumour cells. Fig. I shows the
results obtained in the mixed haemad-
sorption test with various dilutions of
sera from rats with (a) a growing tumour;
(b) 14 days after the tumour has been
excised; and (c) when the excision was
followed by further immunization. It is
quite obvious that no significant levels of
antibody could be detected in the tumour-
bearing serum by this test. Antibody
couldbedetected 14dayspost-excision, but
only at concentrations of I: 4 or greater
and the majority ofthe experiments were,
in fact, carried ouit at a dilution of
1: 3.5. The titre in the hyperimmune
serum was very much higher. The sera
from approximately 30 different rats
bearing an MC-1 tumour in the hind leg
were tested for specific anti-MC-I sarcoma
antibody and in no instance was an MHI
of greater than 1-2 detected. Other
control sera were tested routinely at a
dilution of 1: 3 5 and in no instance
was an MHI of greater than 1 2 detected
(see Table I). Cross-reactions were
obtained only with the hyperimmune sera
raised to other unrelated tumours and
were not seen in the sera of rats with
unrelated tumours which had been ex-
cised. However, the MHI of hyper-
immune sera from animals immunized
against tumours other than the MC-J was
low in comparison with that obtained
withMC-I immune serum onMC-I sarcoma
cells. In absorption studies the MHI fell
to near unity after incubation of MC-I
immune serum with MC-I sarcoma cells.
In contrast, the MHI fell by less than
30% if MC-I immune serum was absorbed
with unrelated sarcoma cells. The cross-
reaction of all unrelated tumour immune
serum onMC-I sarcoma could be abolished
by absorption with unrelated tumour
cells. Parallel investigations (Thomson
and Alexander, 1973) showed that this
cross-reaction in the hyperimmune sera of
different sarcomata is due to the presence
of a membrane antigen of embryonic
origin. This membrane antigen, referred
to as onco-embryonic antigen-I (OEA1)
is antigenic in the syngeneic host.
The rate at which antibody to the
TSTA of MC-I tumour appears following
tumour excision is shown in Fig. 2. After
amputation of the tumour, serum samples
were taken daily. As can be seen serum
anti-TSTA antibody was first detected 6
days after tumour excision and the levels
of anti-TSTA antibody remained elevated
for several months after tumour excision at
a plateau value which was reached after
approximately 15 days.
2. Anti-TSTA antibody in lymph
The method described for obtaining
lymph samples ensured that the animals
remained in a more normal physiological
state than if they were drained conti-
nuously. This was reflected in the stabi-
lity of several parameters. The average
weight loss per animal was less than 00%,
compared with 25% for continuously
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TABLE I. Antibody to MC-I Sarcoma in the Sera ofSyngeneic Rats as Detected
by 5'Cr-labelled-Mixed Haemnadsorption
Origin of sera
Normal rats
Rtats immunized with BCG or Freund's
adjuvant
Rats with unrelated primary sarcoma
Tumour-bearing
14 davs after excision
Rats with growing MC-I tumour
Rats 14 days after MC-I excision
Hlats hyperimmunized with MC-I
Rats hyperimmunized with
Renal tumour
HSH sarcoma (benzpyrene-innluced)
Inferon-induced
MC-3 sarcoma (2'methvl-
cholanthrene-iinduced)
Dilution
of serum
tised
1: 3-5
1: 3-5
: 3-.5
:3- :3a-a
: 3-5
: 8
1:8
Index of mixed
haemadsorptioIl
1-()-1
1-1 1-2
1 *0
1 0-1-2
1 *0-1iI
1 7-2-4
5-0
1 -9
2-5
'' 50
TABLE II. Indirect Membrane Immnunoftuorescence of Mechanically Prepared Single
Cell Suspensions of MC-I (2)
Origin of rat serumI
None (medium 199)
Rats with growing MC-I
tumour
Rats 14 days after
MC-J excision
Rats hyperimmunized
wvith AIC-I sarcoma
Conjugate2 Fltuorescent index4
l
+
I - 5 1-0 1- 23
1-8 1-4 1 '}
.*0 7-0 6-5
13
1 Diltuted I 4.
2 Rabbit anti rat y globulin fluoiescein conjugate (W1'ellcome Rteagents) dilutted 1: 10.
3 V'alues recorded are from 3 separate MIC-I sarcomata in which single cell suspensions were pre(pared
mechanicallv.
Fluorescent index of 2- 5 or greater is significant.
5 Single cell suspensions of MC-I sarcoma prepared by enzymes an(d testedl in parallel ugave i(lentical
fluorescent indices.
drained animals and the intraductural
pressure, lymphocyte output and number
ofcells per ml oflymph remained relatively
constant over a period of up to 15 days.
The lymph of tumour-bearing animals,
when tested at a dilution of 1: 3 5 by
mixed haemadsorption consistently gave
an index of 12 or less. This method
could not be used at higher concentrations
of lymph, since tumour cells detached
from the tissue culture plates ifthe lymph
concentration was higher. Lymph could,
however, be tested at a 1: 2 dilution by
membrane immunofluorescence. Anti-
TSTA antibody was found by membrane
immunofluorescence and the results are
shown in Fig. 3. Five days after tumour
implantation in the hind limb, anti-TSTA
antibody was detectable in the lymph
and its production continued up to the
28th day when the experiment was ter-
minated because the tumours had reached
4 cm in diameter. The fluorescence index
varied from 2-5-4 but showed no consis-
tent trends. A fluorescence index of 2-2
in lymph is significant for the presence of
specific antibody.
Following excision of the tumour,
there was a sharp rise in the level of anti-
TSTA antibody in the lymph and this
antibody could be measured in lymph at a
dilution of 1: 4 in the mixed haemadsorp-
tion test by 2 days after tumour amputa-
tion. The level in the lymph rose con-
tinuously for 7 days following amputation
and then fell, reaching very low levels 14
days after tumour amputation. The tem-
poral relationship of antibody levels in
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FieG. 2. Time sequence of the appearance of anti MC-I tumour-specific antibody in the serum
(0 *) and lymph (0 -O) of animals after excision of their tumour. Serum and
lymph were tested at 1 : 3 - 5 and 1 : 4 dilution respectively by 5'Cr-labelled mixed haemadsorption
test. Each point represents the average of 3 rats per group oIn day indicated.
lymph and blood plasma following tumour
excision are very different. In lymph
the antibody levels rise and then rapidly
fall within a period of 14 days, whereas in
serum there is a continual build-up over
this period and thereafter the value
remains relatively steady (see Fig. 2).
3. Antibody levels in the serum of immune
ratsfollowing a second challenge with MC-I
tumour cells
Fourteen days after surgical excision
of an MC-I tumour, rats are able to resist
an intramuscular challenge with 1 x 106
MC-I sarcoma cells but a larger inoculum
(i.e., in excess of 1 x 107 cells) frequently
gave rise to progressively growing tumours
in these immune animals. Fig. 4 shows
4.0-
24000
Q 2.0_
that following an inoculum of tumour
cells which the immune animals were able
to reject (i.e., 106 tumour cells) antibody
levels in the serum fall precipitously but
beginto recover after2 days andeventually
return to the normal levels. However,
following inoculation of a larger number of
tumour cells (i.e., 2 x 107 tumour cells)
the antibody levels in the serum fell and
remained low. Shortly after the second
tumour became palpable, anti-TSTA anti-
body activity was no longer detectable in
the circulation.
4. Effect of metastases in the lymph node on
circulating antibody
If the tumour was large at the time of
excision then the MC-J tumour in 10% of
t 10
cells inijected days
20 30
Fi(:e. 3.-Time sequlence of the appearainee of anti MC-I tumour-specific aintibody in the lvmph
after inormal rats were injected intramuscularly in the hind limb with 1 x 106 MC-I sarcoma
cells. Lymph was teste(d at 1: 2 dilution by indirect membrane immunofluorescence and a FI of
of 22- or greater is significant.
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FIG. 4. The effect of injecting MC-I cells on the
levels of antibody to MC-1 in rats that had been
immunized by a growing tumour which was
excised 14 days earlier. 1 x 106 C-I cells
(--
--- 0), 2 x 107 cells without progressive
tumour growth ( 0) and with progressive
tumour growth (0 -O). " P " indicates the
time when the tumour was first detectable by
palpation of the hind limb.
rats studied metastasized to the draining
iliac lymph nodes. In rats which were
subsequently found to have such lymph
node metastases, the serum antibody
levels following removal of the primary
were detectable but relatively low 2 weeks
after tumour excision. When the nodes
became palpable 3 weeks after tumour
excision, anti-TSTA antibody activity
was still demonstrable in the serum but
disappeared somne days later. These ex-
periments provide the only examples of
the occurrence of circulating tumour-
specific antibodies in rats having a pro-
gressively growing tumour. Thus, the
only animals with a progressively growing
tumour in which circulating anti-TSTA
antibody was detectable for a considerable
period of time were those with tumour
growing in the lymph node.
5. Inability to detect antibody on the surface
of cells separated from an actively growing
tumour
Single cell suspensions of MC-J sarcoma
prepared mechanically from solid tumours
2 weeks after intramuscular inoculation
were examined for the presence of cell
surface bound immunoglobulins. By the
membrane immunofluorescence test, no
indication could be found for the presence
of anti-TSTA antibody on the surface of
any ofthe tumour cells studied (Table JJ).
On the other hand, such tumour cells
could be shown to bind antibodies specific-
ally if exposed to the serum from animals
from which a tumour had been surgically
removed 14 days earlier.
DISCUSSION
Three mechanisms can be envisaged to
explain the absence of antibody to TSTA
in the serum of animals with progressively
growing antigenic sarcomata: (1) absorp-
tion by the growing tumour of the circu-
lating antibody; (2) failure of antibody
production while the tumour is in situ as a
result ofimmunological tolerance; (3) com-
plexing of the antibody in the circulation
by soluble TSTA from the growing
tumour.
While the experiments reported do not
exclude the possibility that some of the
antibody produced is taken up by the
solid tumour, this is clearly not the only
mechanism responsible for the absence of
detectable antibody in tumour-bearing
animals. This is shown by the measure-
ments of antibody level in thoracic duct
lymph. The fact that this level is very
low in animals with a growing tumour and
rises soon after tumour excision cannot be
explained by combination with the tumour
since the antibody in lymph is derived
directly from the stimulated node before
it has had an opportunity to come into
contact with the tumour. The finding
that circulating antibody can be found in
animals with tumours growing in the
lymph nodes which would be expected to
adsorb antibody from the circulation at
least as effectively as tumours growing
intramuscularly, also suggests that the
failure to detect free antibody in animals
with intramuscular tumours is unlikely
to be due to direct absorption by the
tumour.
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The possibility that the absence of
antibody activity in serum of tumour
bearers is due to a central failure of anti-
body production while the tumour is in
situ (i.e., immunological tolerance) is
excluded by the detection of low levels of
antibody in lymph and by experiments
which show that the serum of tumour-
bearing rats contain complexes of soluble
tumour antigen and specific antibody
(Thomson et al., 1973). This hypothesis
is also not consistent with the finding
that animals having residual metastatic
tumour growing in lymph nodes have
circulating antibody in their serum, nor
with the rapid rise of antibody in the
lymph following tumour excision. There
remains the possibility that immunological
responsiveness is regulated by the pres-
ence of antigen-antibody complexes in
relative antigen excess and that a partial
and evanescent tolerance may occur
(Sinclair and Chan, 1971) but again this
would be difficult to reconcile with the
rapid rise in antibody activity in the
lymph after tumour removal. Following
excision ofthe tumour, there is initially an
exponential increase of the rate of specific
antibody production as measured by
the level in the lymph. After 8 days or
so the rate of antibody production by the
draining nodes falls rapidly and 14 days
after excision no antibody can be detected
in the lymph while the serum levels are at
their maximum at this time. The fact
that 14 days after amputation there is a
very wide divergence in antibody levels
in lymph and blood plasma is a reflection
of the dynamics of antibody synthesis
(cf. Gurvitch and Nikolaeva, 1971) and of
the unequal partition of macromolecules
between blood and lymph (Hall et al.,
1969). Although all fractions of the
plasma proteins are present in lymph,
they are not present in the same propor-
tions as in blood because proteins of high
molecular weight extravasate less readily
from blood to extracellular fluids.
The data presented in this paper
suggest that the principal reason for failing
to find antibody in the circulation of
tumour-bearing animals is that soluble
TSTA is released by the tumour and that
the low level of specific antibody released
from stimulated nodes into the lymph of
tumour-bearing animals is due to its
continuous complexing with free soluble
antigen which drains from the tumour to
the lymph nodes. That residual meta-
static tumour growing in a lymph node
does not initially interfere with antibody
activity in the serum as effectively as
does a tumour growing intramuscularly
may arise from the failure of released
antigen to leave the node. While the
tumour in the node is small, antigen
binding cells such as the dendritic reticular
cells and macrophages may trap the
antigen within the involved node. How-
ever, as the tumour grows the architecture
of the involved nodes becomes grossly
distorted and may then permit antigen to
gain access to the lymph and the circula-
tion, and neutralize the circulating anti-
body. Other studies with the MC-I tumour
also indicate that soluble TSTA is released
by the tumour and complexes with anti-
bodies both in the blood and the lymph.
Thus in the circulation of tumour-bearing
animals excess free antigen and complexes
ofantigen-antibody were found (Thomson
et al., 1973).
Our studies suggest that there are
several mechanisms by which the TSTA of
the MC-J sarcoma reaches the circulation
of a soluble low molecular weight
(<100,000 daltons) macromolecule. Cir-
culating TSTA was not detected if rats
into which the tumour has been implanted
were sufficiently immunosuppressed by
whole body irradiation (Thomson et al.,
1973) so as not to form specific antibody.
This suggests that the release ofthe TSTA
occurs as a by-product of an immune
reaction. The recent demonstration by
Amos, Cohen and Klein (1970) that anti-
body does not remain for prolonged
periods of time on the surface of tumour
cells maintained in tissue culture suggests
that specific antibody can elute TSTA
from the cell membrane.
The precipitous fall in antibody levels
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in immune animals which follows the
injection of 106 tumour cells which are
rejected (see Fig. 4), is explained most
readily by the release of soluble antigen
into the circulation from tumour cells
that are being destroyed specifically at the
site of inoculation. In addition, soluble
TSTA is released into the circulation
following non-immunological destruction
ofthe tumour cells. This was shown using
a recently developed technique (Thomson,
in course of publication) by which the
blood levels of TSTA from MC-J sarcoma
were measured directly by radioimmuno-
assay. It was found that when live
tumour cells were injected into normal
(i.e., non-immune) rats considerable quan-
tities ofsoluble TSTA were released within
24 hours.
It is possible that the biological
behaviour of antigenic tumours may be
determined in part by the relative ease
with which release of soluble low mole-
cular TSTAs occur. We speculate that a
rapid rate of spontaneous release of
soluble TSTA-a phenomenon not appar-
ently seen with the MC-I may facilitate
escape from host control and therefore be
associated with a high degree of malig-
nancy. The MC-I tumour is relatively
benign; it metastasizes in less than 100%
of rats and most animals can be cured by
surgical excision of the primary.
Whatever the mechanisms of release,
the experiments reported showthattumour
transplantation is associated with a per-
sisting release of soluble antigen into the
circulation. This antigenic burden is
continuously present and continually
renewed as long as the tumour mass exists
and has been shown to affect the humoral
immune response and might be expected
to interfere also with specific cell-mediated
immunological responses to the tumour.
Studies by Currie and Basham (1972) and
Baldwin et al. (1973) support the idea that
excess antigen may act on the lymphocyte
surface and impair the capacity of cyto-
toxic lymphocytes to kill the specific
target cells. The tumour specific " block-
ing " factor in the serum of patients with
cancer, at one time postulated to be anti-
body, has now been attributed to com-
plexes oftumour antigen with antibody by
Sjogren et al. (1971). Our data draw
attention to the soluble tumour antigens
that escape the tumour mass and become
available to interact systemically with
elements of the lymphoreticular system.
It is suggested, as have others (Smith,
1972), that tumour antigen excess may be
a dominant element in the tumour-host
relationship.
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